Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design-Reference-Cited by-同舟云学术

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design

Published:2007-11 Issue:6 Volume:28 Page:770-779
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Siami Paul,Roehrborn Claus G.,Barkin Jack,Damiao Ronaldo,Wyczolkowski Marek,Duggan Annette,Major-Walker Kim,Morrill Betsy B.

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference26 articles.

1. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Information accessed September 2006. Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement.

2. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia;Napalkov;Urology,1995

3. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists;Barry;J Urol,1997

4. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group;McConnell;N Engl J Med,1998

5. Natural history of prostatism: risk factors for acute urinary retention;Jacobsen;J Urol,1997

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia;The Prostate;2023-12-27

2. Roles of NF-κB activation in benign prostatic hyperplasia and association between NF-κB and HIF-1α;Pathology - Research and Practice;2022-09

3. Characteristics of Patients Who Visit Urologic Outpatient Department via Health Promotion Center;The Korean Journal of Urological Oncology;2022-08-31

4. Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort;Minerva Urology and Nephrology;2022-03

5. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia;BMC Urology;2021-03-27